QLS1317

QLS1317 is a recombinant humanized bispecific monoclonal antibody that simultaneously targets Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4). Developed by Qilu Pharmaceutical, the drug is designed to enhance the anti-tumor immune response by dual blockade of these critical immune checkpoints, which may overcome resistance mechanisms associated with single-agent checkpoint inhibition. QLS1317 is currently undergoing Phase I clinical evaluation for the treatment of advanced solid tumors, specifically focusing on patients with Microsatellite Instability-High (MSI-H) or deficient DNA Mismatch Repair (dMMR) status who have failed standard-of-care therapies.